Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. g125

G125 SIGNED

A minimally invasive, outpatient treatment for Gastroesophageal Reflux Disease (GERD), resulting in permanent relief from both GERD symptoms and life-long drug dependency

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 G125 project word cloud

Explore the words cloud of the G125 project. It provides you a very rough idea of what is the project "G125" about.

clinical    chain    responders    consists    efs    endoscopic    gastro    medication    esophageal    content    anti    lower    catheter    area    thereby    treat    ppis    vascular    syringe    15    tissue    ingrowth    heartburn    suspended    diagnosis    inhibitors    biocompatible    made    flexible    strategy    agent    disease    gastric    people    supply    sphincter    12    perform    bovine    intervention    stimulated    caused    treatment    medications    cure    unfortunately    polymethylmethcrylate    mask    transition    reflux    cell    injection    invasive    g125    bore    debilitating    sufferers    surgical    underlying    gerd    million    barrier    union    refine    gastroesophageal    outpatient    followed    enzymes    least    innovation    proton    market    trial    permanent    digestive    commercialization    fibro    integrity    plan    severe    ascentx    medical    needle    prepare    drafted    les    pmma    gastroenterological    injectable    esophagal    option    bulking    patients    scaffold    daily    20    acid    disorder    microspheres    root    collagen    uses    symptoms    regurgitation    elongated    normal    procedure    pump   

Project "G125" data sheet

The following table provides information about the project.

Coordinator		 ASCENTX MEDICAL EUROPE LIMITED 

Organization address
address: UNIT 6 QUEENS YARD, WHITE POST LANE
city: LONDON
postcode: E95EN
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country United Kingdom [UK]
 Project website http://ascentxmedical.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-09-01   to  2019-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ASCENTX MEDICAL EUROPE LIMITED UK (LONDON) coordinator 50˙000.00

Map

 Project objective

Gastroesophageal Reflux Disease (GERD) is a digestive disorder associated with symptoms such as heartburn and regurgitation, and reflux of normal gastric content like gastric acid and digestive enzymes. GERD is caused by a loss of integrity of the gastro-esophageal barrier known as the 'lower esophageal sphincter' (LES). This condition is one of the most common gastroenterological diagnosis in the European Union, with an estimated 15-20 Million daily sufferers. GERD today is typically treated with medications such as proton pump inhibitors (PPIs). Unfortunately, these anti-acid medications only ‘mask’ GERD symptoms, cause severe side-effects long-term, and about 20% of patients are non-responders. Importantly, they do not treat/cure the underlying root cause of acid reflux. For people who have severe GERD and do not respond to medication, invasive surgical intervention remains the only option. G125 is the least invasive outpatient treatment for Gastroesophageal Reflux Disease (GERD). It is a permanent injectable bulking agent for the endoscopic treatment which enables cell growth in the Lower Esophagal Sphincter (LES), thereby providing long term cure for the debilitating symptoms of GERD. G125 uses a tissue-friendly (biocompatible) microspheres made of Polymethylmethcrylate (PMMA) suspended in bovine collagen and an Elongated Flexible Syringe (EFS) which consists of an elongated catheter and a transition bore needle. The PMMA microspheres provide a permanent scaffold for stimulated fibro-vascular tissue ingrowth in the affected area. During the phase 1 project, a go-to-market strategy and a supply chain will be established, as well as further development plan will be drafted. Within the overall innovation project AscentX Medical will refine the endoscopic injection procedure, perform a 12 month clinical trial with 60 patients followed by a scale up of the production to prepare for commercialization.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "G125" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "G125" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

TAPPXSSAI (2019)

Development of a system for automatic ad insertion into on-demand streaming video to provide new monetization mechanisms to the media industry

Read More  

BeatsDigTherapeutics (2019)

Project SCALE: Tailored Digital Therapeutics for Neurological and Brain Disorders

Read More  

PRIVATETRACK (2019)

PRIVATETRACK: Privacy-friendly, low-power intelligent room occupancy detection and people counting.

Read More